Literature DB >> 32880537

The utility of high-flow nasal cannula oxygen therapy in the management of respiratory failure secondary to COVID-19 pneumonia.

U Lalla1, B W Allwood, E H Louw, A Nortje, A Parker, J J Taljaard, D Moodley, C F N Koegelenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32880537

Source DB:  PubMed          Journal:  S Afr Med J


× No keyword cloud information.
  4 in total

1.  The effectiveness of high-flow nasal cannula and standard non-rebreathing mask for oxygen therapy in moderate category COVID-19 pneumonia: Randomised controlled trial.

Authors:  N Nazir; A Saxena
Journal:  Afr J Thorac Crit Care Med       Date:  2022-05-05

2.  The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: A multi-centre prospective observational study.

Authors:  Gregory L Calligaro; Usha Lalla; Gordon Audley; Phindile Gina; Malcolm G Miller; Marc Mendelson; Sipho Dlamini; Sean Wasserman; Graeme Meintjes; Jonathan Peter; Dion Levin; Joel A Dave; Ntobeko Ntusi; Stuart Meier; Francesca Little; Desiree L Moodley; Elizabeth H Louw; Andre Nortje; Arifa Parker; Jantjie J Taljaard; Brian W Allwood; Keertan Dheda; Coenraad F N Koegelenberg
Journal:  EClinicalMedicine       Date:  2020-10-06

3.  Comparison of patients with severe COVID-19 admitted to an intensive care unit in South Africa during the first and second wave of the COVID-19 pandemic.

Authors:  U Lalla; C F N Koegelenberg; B W Allwood; L N Sigwadhi; E M Irusen; A E Zemlin; T E Masha; R T Erasmus; Z C Chapanduka; H Prozesky; J Taljaard; A Parker; E H Decloedt; F Retief; T P Jalavu; V D Ngah; A Yalew; J L Tamuzi; N Baines; M McAllister; A Zumla; P S Nyasulu
Journal:  Afr J Thorac Crit Care Med       Date:  2021-12-31

4.  Update Alert 2: Ventilation Techniques and Risk for Transmission of Coronavirus Disease, Including COVID-19.

Authors:  Rebecca Thomas; Tamara Lotfi; Gian Paolo Morgano; Andrea Darzi; Marge Reinap
Journal:  Ann Intern Med       Date:  2020-10-13       Impact factor: 25.391
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.